FDA approves Theratechnologies' Egrifta - first drug for HIV lipodystrophy
This article was originally published in Scrip
Executive Summary
The US FDA has approved an NDA from Montreal-based Theratechnologies for Egrifta (tesamorelin for injection) as the first and only treatment indicated to reduce excess abdominal fat in HIV-infected patients with lipodystrophy. The approval follows a unanimous endorsement by the FDA's endocrinologic and metabolic drugs advisory committee earlier this year (scripintelligence.com, 28 May 2010).